战略性新兴产业框架下的医药企业专利策略与创新能力建设

丁锦希, 孟立立, 张金凤

中国药学杂志 ›› 2014, Vol. 49 ›› Issue (5) : 431-436.

PDF(5081 KB)
PDF(5081 KB)
中国药学杂志 ›› 2014, Vol. 49 ›› Issue (5) : 431-436. DOI: 10.11669/cpj.2014.05.021
药事管理

战略性新兴产业框架下的医药企业专利策略与创新能力建设

  • 丁锦希, 孟立立, 张金凤
作者信息 +

Pharmaceutical Corporate Patent Strategy and Innovation Capacity-Building under the Framework of the Strategic Emerging Industries

  • DING Jin-xi, MENG Li-li, ZHANG Jin-feng
Author information +
文章历史 +

摘要

目的 为我国医药企业专利策略的开展和创新能力的建设提供可行性建议。方法 选取一类创新药物恩必普为实证研究对象, 从专利创造、管理和实施3个方面, 就该企业如何充分利用国家创新政策和专利战略以提高企业创新能力, 保证企业可持续发展进行实证检验。结果 恩必普的专利策略获得了较好的实施绩效。结论 石药集团形成了专利战略运用与企业创新能力提升相互促进共同发展的良性循环, 其成功经验, 值得我国高新技术企业学习借鉴。

Abstract

OBJECTIVE To provide domestic innovative pharmaceutical enterprises practical advice on patent strategy and innovation capacity-building. METHODS Choose the first class innovative drug NBP as study subject, make an empirical study from three aspects, including patent creation, management and implementation, about how to take full advantage of the national innovation policies and patent strategy to improve the innovation capability of enterprises to ensure its sustainable development.RESULTS The patent strategy of NBP turns out to be a very big success. CONCLUSION CSPC has developed a virtuous cycle, in which patent strategy and innovation capacity-buildingfacilitate each other, its successful experience is worth learning for high-tech enterprises.

关键词

战略性新兴产业 / 专利策略 / 企业创新能力建设

Key words

strategic emerging industry / patent strategy / innovation capacity-building

引用本文

导出引用
丁锦希, 孟立立, 张金凤. 战略性新兴产业框架下的医药企业专利策略与创新能力建设[J]. 中国药学杂志, 2014, 49(5): 431-436 https://doi.org/10.11669/cpj.2014.05.021
DING Jin-xi, MENG Li-li, ZHANG Jin-feng. Pharmaceutical Corporate Patent Strategy and Innovation Capacity-Building under the Framework of the Strategic Emerging Industries[J]. Chinese Pharmaceutical Journal, 2014, 49(5): 431-436 https://doi.org/10.11669/cpj.2014.05.021
中图分类号: R95   

参考文献

FENG X Q. Enterprise Intellectual Property Strategy(企业知识产权战略) . 2nd ed. Beijing: Intellectual Property Publishing House, 2005:10-11. GUO D H. Research on patent strategic of multinational pharmaceutical companies in china and its enlightenment to traditional chines medicine industry. China Academy of Chinese Medical Science, 2008. SHAO R. Theory and Practice of Chinese Pharmaceutical Law(中国药事法理和实务). Beijing: China Medical Science Press, 2010:261-262. BEIJING BUSINESS DAILY: CSPC entered into Korean market. .Sina Finance, 2007 . http://finance.sina.com.cn/roll/20071122/00131806992.shtml. ZHONG Z H. What makes an innovative drug wait for 2 years before entering the medical insurance catalog. China Prescr Drug(中国处方药), 2009, 7(88):13.

基金

国家社会科学基金项目(10cFX055);国家知识产权局软课题项目(ss09-A-26;SS11-A-21)
PDF(5081 KB)

175

Accesses

0

Citation

Detail

段落导航
相关文章

/